Study of Canakinumab in Patients With Myelofibrosis
Key claim: A phase 2 trial is evaluating canakinumab, an anti-IL-1β monoclonal antibody, as a treatment for primary myelofibrosis and post-ET/PV myelofibrosis using a two-stage design with efficacy and safety stopping rules.
Abstract
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles. Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks. The interim analysis will be performed when the number of enrolled patients reaches 10. If no responses OR 4 or more patients have unacceptable toxicity, the study will not proceed to the second stage. If the total number of patients reaches the maximum sample size of 26, the treatment is deemed acceptable if the number of responses in the efficacy endpoint are greater than 3, and the number of toxicities are less than 7.
Why this matters
Canakinumab represents the first clinical test of selective IL-1β neutralization in myelofibrosis, extending the inflammatory-cytokine therapeutic hypothesis (previously explored via tasquinimod’s S100A9 axis and JAK-driven cytokine suppression) to a discrete, well-validated cytokine target. Because the trial spans PMF and post-ET/post-PV MF, it offers a chance to compare IL-1β-driven biology across primary versus secondary fibrotic disease and could differentiate transformation subtypes by inflammatory dependence. A two-stage efficacy/safety design appropriately gates a high-novelty mechanism in a frail population.